Intrasense SA (ALINS) AI Stock Analysis

• Market Cap: €12.49M
• Dividend Yield: N/A
• Average Volume (3M): 21.02K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.14
• Revenue Growth: 13.56%
• EPS Growth: -65.50%
• Country: US
• Employees: 76
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.05
• Shares Outstanding: 52,716,263
• 10 Day Avg. Volume: 15,382
• 30 Day Avg. Volume: 21,018
• PEG Ratio: -0.04
• Price to Book (P/B): 7.33
• Price to Sales (P/S): 5.40
• P/FCF Ratio: -2.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): €4.60M

• Rating: 41 Neutral
• Price Target: €0.24 ▲(3.04% Upside)

The score is primarily held down by weak financial performance—declining revenue, negative margins, ongoing losses, high leverage, and negative operating/free cash flow. Technicals add modest support in the very short term but remain broadly weak versus longer-term moving averages and negative MACD. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.

Positive Factors

Recurring subscription model

A subscription-based licensing model creates recurring revenue and service relationships with healthcare institutions. Over months this improves revenue predictability, supports multi-year customer retention, and can enable more stable cash flow to fund product development and support investments.

Focused imaging software portfolio

Specialization in advanced medical imaging positions the company in a niche with durable demand from radiology workflows. Domain-focused products can create higher switching costs, clinical integration advantages, and sustained adoption by hospitals and imaging centers over a multi-quarter horizon.

Top-line growth metric

Reported revenue growth of about 13.6% signals improving sales momentum. If sustained alongside the subscription model, this growth can compound recurring revenue, improve operational leverage and margins over several quarters, reducing dependency on external financing for operations.

Negative Factors

Negative margins and operating losses

Negative gross and net margins and persistent operating losses indicate the core business is not yet profitable. Over months this erodes reserves, limits reinvestment capacity, and makes breakeven harder to reach without sustained margin improvement or cost structure changes.

High leverage and weak equity base

A high debt-to-equity ratio and low equity ratio reduce financial flexibility and raise refinancing risk. Over the medium term this can increase interest burdens, constrain R&D and commercialization spending, and make the company more vulnerable to adverse funding conditions.

Negative operating and free cash flow

Negative operating and free cash flow point to ongoing cash burn and weak cash generation. Over several months this typically necessitates external financing or cost cuts, which can dilute shareholders or constrain growth investments and jeopardize long-term product rollouts.

Intrasense SA Business Overview & Revenue Model

Company Description

Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams. The company was incorporated in 2004 and is headquartered in Montpellier, France.

How the Company Makes Money

Intrasense generates revenue primarily through the sale and licensing of its software solutions to healthcare institutions, including hospitals and imaging centers. The company employs a subscription-based model for its software, which provides a recurring revenue stream as clients pay for ongoing access and support. Additionally, Intrasense may generate revenue through partnerships with medical device manufacturers and healthcare providers, offering integrated solutions that enhance their existing offerings. Training and support services for its software also contribute to the company's earnings, as healthcare organizations seek to ensure that their staff can effectively utilize Intrasense's products.

Intrasense SA Financial Statement Overview

Summary

Financial statements indicate material weakness: declining revenue, negative gross and net margins, and persistent operating losses. The balance sheet shows high leverage with low equity and negative ROE, while cash flow is negative (operating and free cash flow), signaling ongoing cash burn and elevated financial risk.

Income Statement

Intrasense SA has been experiencing declining revenue with a negative trend in profitability. The gross profit margin is negative, indicating cost of goods sold exceeds revenue. Net profit margin is also negative, reflecting consistent net losses. There is a concerning decline in revenue over the years, with significant operating losses as evidenced by negative EBIT and EBITDA margins.

Balance Sheet

The company's balance sheet shows a high debt-to-equity ratio, indicating reliance on debt financing. The equity ratio is low, reflecting potential financial instability. Return on equity is negative, indicating that shareholders are not seeing returns on their investment. These factors suggest financial vulnerability and limited equity to cover liabilities.

Cash Flow

Intrasense SA reports negative operating cash flow and free cash flow, highlighting cash burn and operational challenges. The company is not generating sufficient cash from operations to cover expenses, and free cash flow is declining, indicating worsening cash position over time. The operating cash flow to net income ratio is negative, suggesting poor cash earnings quality.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.65M	2.25M	3.31M	3.79M	4.19M	3.44M
Gross Profit	-6.07M	-3.81M	-885.00K	-1.15M	-1.05M	-454.00K
EBITDA	-5.37M	-4.60M	-2.68M	-2.09M	-611.00K	-30.00K
Net Income	-6.48M	-5.66M	-3.58M	-3.42M	-1.20M	-704.00K
Balance Sheet
Total Assets	9.19M	7.68M	10.45M	6.51M	8.77M	6.36M
Cash, Cash Equivalents and Short-Term Investments	1.44M	930.00K	4.55M	1.41M	4.76M	2.59M
Total Debt	1.37M	1.58M	1.49M	2.06M	1.93M	2.26M
Total Liabilities	10.36M	6.03M	3.17M	4.50M	3.78M	4.21M
Stockholders Equity	-1.16M	1.65M	7.29M	2.01M	4.99M	2.15M
Cash Flow
Free Cash Flow	-6.50M	-5.94M	-4.97M	-3.48M	-1.50M	-1.08M
Operating Cash Flow	-4.62M	-3.73M	-3.05M	-2.00M	-948.00K	-481.00K
Investing Cash Flow	-1.86M	-2.21M	-1.93M	-1.49M	-555.00K	-551.00K
Financing Cash Flow	6.61M	2.33M	8.10M	98.00K	3.62M	2.71M

Intrasense SA Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.23
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALINS, the sentiment is Neutral. The current price of 0.23 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.25, and below the 200-day MA of 0.28, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 39.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALINS.

Intrasense SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALIKO	50 Neutral	€25.26M	-6.75	-16.42%	―	138.92%	11.14%
ALMDT	47 Neutral	€170.97M	-4.08	―	―	6.75%	15.48%
ALINS	41 Neutral	€12.49M	-1.95	-314.39%	―	13.56%	-65.50%
ALAMA	41 Neutral	€8.57M	-1.50	―	―	-9.75%	36.83%